The conclusion of the above results analysis is that Enterosgel is well tolerated during radiotherapy and that taking it reduces gastrointestinal problems, which are accompanied by reduction of weight loss. In order to confirm the efficacy of Enterosgel in prevention of gastrointestinal (as well as other) adverse reactions connected to radiotherapy, it is necessary to include more patients, although preliminary results indicate that Enterosgel can be recommended as a supportive treatment to increase the quality of life during pelvic radiation.

Matković et al., 2016*, used Enterosgel as a supportive treatment during external radiotherapy in patients with uterine and cervical cancer. During the period from 01.07.2014. to 30.10.2015 they examined 90 patients with uterine or cervical cancer who were treated by external pelvic radiotherapy. Patients were divided into 2 groups: Group 1 included 46 patients who were given 3×1 table spoon (45 g/day) of Enterosgel for 5 weeks, and Group 2 (control) included 44 patients who did not take Enterosgel. No significant differences between the two groups were found for erythrocytes, leukocytes and thrombocytes count; during radiotherapy, all patients had a mild reduction of those parameters.

ECOG also did not show any difference between study groups. Body weight showed statistical difference between study groups. Patients in the control group have lost an average of 0.49 to 2.17 kg more than patients who did take Enterosgel (p < 0.01). The number of diarrhoeal stools during five weeks also showed statistical difference between the groups. Patients taking Enterosgel had 0.47 to 6.29 diarrhoeal stools less than patients in the control group (p < 0.05). Patients taking Enterosgel during 5-week period had, in average, 1.03 to 5.71 days fewer with than patients not taking Enterosgel (p<0.01).

The authors related the therapeutic effect of Enterosgel to its ability for adsorbing large molecular weight substances, which is important in the cancer patients undergoing chemo- and/or radiotherapy. They concluded that Enterosgel can be recommended to patients receiving pelvic radiotherapy or concomitant pelvic chemoradiotherapy, as a supportive treatment for reducing the chemoradiotherapy complications, such as frequent stools, nausea and subsequent loss of body weight. Interestingly, the authors pointed out that low adsorption capacity of Enterosgel towards small molecules such as medicines, in comparison with activated charcoal, makes it convenient to use concomitantly with practically any pharmacological product for oral administration.

The results presented by Matković et al., 2016, are in agreement with an earlier work published by Sakhno et al., 2013, who studied enterosorption effect on reduction of systemic toxicity of cisplatin in rats. They reported that administering Enterosgel reduced the weight loss by 1.6 times compared to the group, which did not receive the adsorbent. They noticed that enterosorption had a positive effect on the renal function in cisplatin treated rats: Enterosgel prevented creatinine increase (that was approximately 30% in animals that did not receive Enterosgel) and reduced increase of plasma level of urea, which points to beneficial effect on glomeruli. Enterosgel also had beneficial effect on liver in rats treated with cisplatin, which was evidenced by aspartate transaminase level (animals that received Enterosgel had same values as intact animals).

Clinical evidences

EXPERIMENTAL CLINICAL STUDY OF ENTEROSGEL (METHYLSILICIC ACID HYDROGEL) APPLICATION IN ONCOLOGY PATIENTS DURING THE COURSES OF GAMMA TELETHERAPY AND CHEMORADIOTHERAPY

Shevchenko Yu.N., Serezhko Yu.A. Federal State Prof. A.I. Kolomiychenko Institute of Otolaryngology of the AMS of Ukraine, Kiev, Ukraine, 2001 Open

ENDOSCOPIC METHOD OF INTESTINAL DECOMPRESSION WITH THE USE OF ENTERO- AND COLONOSORPTION IN TREATMENT OF RECTAL CANCER COMPLICATED WITH INTESTINAL OBSTRUCTION

O.E. Kalinin. Lugansk Regional Clinical Oncological Dispensary, Lugansk, Ukraine. R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine Open

Enterosgel as a supportive treatment during external radiotherapy in patients with uterine and cervical cancer

Višnja Matković, Kristina Katić, Ante Ćorušić. Division of gynaecologic oncology. Women’s health clinic, University Hospital Centre Zagreb, Zagreb